公开(公告)号：US07384639B2

公开(公告)日：2008-06-10

申请号：US11220224

申请日：2005-09-06

Applicant: Andrew S. Kende ,  Barbara H. Iglewski ,  Roger Smith ,  Richard P. Phipps ,  James P. Pearson

Inventor： Andrew S. Kende ,  Barbara H. Iglewski ,  Roger Smith ,  Richard P. Phipps ,  James P. Pearson

IPC: A61K39/385 ,  A61K39/02 ,  A61K39/108 ,  A61K39/106 ,  A61K39/00

CPC classification number: C07D207/273 ,  A61K39/385 ,  A61K2039/505 ,  A61K2039/6081 ,  C07D263/26 ,  C07D307/33 ,  C07D333/36 ,  C07K16/1203 ,  C07K16/1214 ,  G01N33/56911 ,  Y10S435/975 ,  Y10S436/80 ,  Y10S436/804 ,  Y10S530/806 ,  Y10S530/808

Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.

Abstract translation: 本发明涉及包含与革兰氏阴性细菌的自身诱导剂偶联的载体分子的免疫原性缀合物。当与药学上可接受的载体组合时，免疫原性缀合物形成用于哺乳动物以防止革兰氏阴性细菌感染的合适疫苗。免疫原性缀合物 也用于提高和随后分离能够识别和结合自动诱导剂的抗体或其结合部分。 抗体或其结合部分用于治疗感染的方法，抑制自身诱导剂活性的方法，以及用于检测流体或组织样品中自身诱导剂或自身诱导剂拮抗剂的存在的诊断测定。

公开(公告)号：US20070189982A1

公开(公告)日：2007-08-16

申请号：US11654512

申请日：2007-01-18

Applicant: Eric Reynolds ,  Peter Bhogal ,  Nada Slakeski

Inventor： Eric Reynolds ,  Peter Bhogal ,  Nada Slakeski

IPC: A61K39/40 ,  A61K39/02 ,  A61K8/96 ,  C07K16/12

CPC classification number: C12N9/52 ,  A61K8/64 ,  A61K38/00 ,  A61K39/00 ,  A61Q11/00 ,  C07K16/1203 ,  G01N33/56955

Abstract: This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell association protein complex comprising the PrtR and PrtK proteins. Accordingly the invention provides a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa. The invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.

Abstract translation: 本发明涉及牙龈卟啉单胞菌PrtR-PrtK细胞表面蛋白，特别涉及包含PrtR和PrtK蛋白的多聚细胞关联蛋白复合物。 因此，本发明提供了用于提高针对牙龈卟啉单胞菌的抗体应答的基本上纯化的抗原复合物。 复合物包含精氨酸特异性和赖氨酸特异性硫醇内肽酶的至少一种多聚体蛋白质复合物，其各自含有至少一个粘附素结构域，所述复合物具有大于约200kDa的分子量。 本发明还涉及基于用于检测，预防和治疗牙龈卟啉菌相关牙周病的所述复合物的药物组合物和相关剂。

公开(公告)号：US20070003991A1

公开(公告)日：2007-01-04

申请号：US11158800

申请日：2005-06-22

Applicant: Malik Merza

Inventor： Malik Merza

IPC: G01N33/554 ,  C12N5/06 ,  C07K16/12

CPC classification number: G01N33/56922 ,  C07K16/12 ,  C07K16/1203 ,  C12Q1/04

Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.

Abstract translation: 本发明涉及动物健康领域，特别涉及细胞内劳森氏菌。 特别地，本发明涉及诊断细胞内劳森氏菌感染的方法，以及使用细胞内劳森氏菌特异性抗体的诊断测试试剂盒。 本发明还涉及该方法或测试试剂盒用于诊断细胞内劳森氏菌感染的用途。

公开(公告)号：US06958219B2

公开(公告)日：2005-10-25

申请号：US10772599

申请日：2004-02-05

Applicant: Andrew S. Kende ,  Barbara H. Iglewski ,  Roger Smith ,  Richard P. Phipps ,  James P. Pearson

Inventor： Andrew S. Kende ,  Barbara H. Iglewski ,  Roger Smith ,  Richard P. Phipps ,  James P. Pearson

IPC: A61K39/385 ,  C07D207/26 ,  C07D207/273 ,  C07D263/26 ,  C07D307/33 ,  C07D333/36 ,  C07K16/12 ,  G01N33/53 ,  G01N33/542 ,  G01N33/559 ,  G01N33/569

CPC classification number: C07D207/273 ,  A61K39/385 ,  A61K2039/505 ,  A61K2039/6081 ,  C07D263/26 ,  C07D307/33 ,  C07D333/36 ,  C07K16/1203 ,  C07K16/1214 ,  G01N33/56911 ,  Y10S435/975 ,  Y10S436/80 ,  Y10S436/804 ,  Y10S530/806 ,  Y10S530/808

Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.

Abstract translation: 本发明涉及包含与革兰氏阴性细菌的自动诱导剂偶联的载体分子的免疫原性缀合物。 当与药学上可接受的载体组合时，免疫原性缀合物形成用于哺乳动物的合适的疫苗，以防止革兰氏阴性菌感染。 免疫原性缀合物也用于引发和随后分离能够识别和结合自动诱导剂的抗体或其结合部分。 抗体或其结合部分用于治疗感染的方法，抑制自身诱导剂活性的方法，以及用于检测流体或组织样品中自身诱导剂或自身诱导剂拮抗剂的存在的诊断测定。

公开(公告)号：US20050031647A1

公开(公告)日：2005-02-10

申请号：US10891745

申请日：2004-07-15

Applicant: Michael Roof ,  Jeremy Kroll ,  Jeffrey Knittel

Inventor： Michael Roof ,  Jeremy Kroll ,  Jeffrey Knittel

IPC: C07K16/12 ,  C12N1/21 ,  A61K48/00 ,  A61K39/02 ,  C12P21/04

CPC classification number: A61K39/105 ,  A61K2039/505 ,  A61K2039/521 ,  A61K2039/522 ,  C07K16/1203 ,  G01N2333/195 ,  Y10S424/825

Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

Abstract translation: 本发明涉及细胞内劳森氏菌疫苗以及用于保护和诊断细胞内感染的方法。 本发明的产品和方法部分地可以通过用于培养大量细胞内源性物质的改进方法的结果，所述方法包括欧洲来源的​​细胞内分泌物的新型分离物和制备冻干产物的方法 含有减毒的欧洲分离物作为疫苗产品。

公开(公告)号：US20030215402A1

公开(公告)日：2003-11-20

申请号：US10283024

申请日：2002-10-28

Inventor： Ian George Barr ,  Larissa Czajkowski ,  Bruce Carter Ross

IPC: G01N033/554 ,  G01N033/569 ,  C07H021/04 ,  A61K039/02 ,  C12P021/02 ,  C12N001/21 ,  C07K014/195

CPC classification number: C07K16/1203 ,  A61K38/00 ,  A61K39/00 ,  C07K14/195 ,  Y10S530/806 ,  Y10S530/825

Abstract: The present invention relates to soluble P. gingivalis polypeptides derived from PG32 and PG33 and to polynucleotides encoding these polypeptides. The P. gingivalis polypeptides and nucleotides can be used in compositions for use in raising an immune response in a subject against P. gingivalis and treating or preventing or reducing the severity of the condition known as periodontitis or in other conditions related to infection with P. gingivalis.

Abstract translation: 本发明涉及源自PG32和PG33的可溶性牙龈卟啉单胞菌多肽和编码这些多肽的多核苷酸。 牙龈卟啉菌多肽和核苷酸可用于组合物中，用于提高受试者针对牙龈卟啉单胞菌的免疫应答，并且治疗或预防或降低称为牙周炎或其他与感染P的病症的严重性。 牙龈卟啉菌

公开(公告)号：US06632437B1

公开(公告)日：2003-10-14

申请号：US08153263

申请日：1993-11-15

Applicant: Rachel Schneerson ,  John B. Robbins ,  J. N. Sarvamangala Devi

Inventor： Rachel Schneerson ,  John B. Robbins ,  J. N. Sarvamangala Devi

IPC: A61K39385

CPC classification number: C07K16/1203 ,  A61K38/00 ,  A61K39/095 ,  A61K47/646 ,  A61K2039/6037

Abstract: The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.

Abstract translation: 本发明涉及多糖 - 蛋白质结合物。 本发明还涉及使用缀合物来预防全身感染的方法。 本发明还涉及药物组合物。 本发明还涉及一种生产多糖 - 蛋白质结合物的方法

公开(公告)号：US20020177200A1

公开(公告)日：2002-11-28

申请号：US09813214

申请日：2001-03-20

Applicant: Antex Biologics Inc.

Inventor： Kenneth Tucker ,  Laura Plosila

IPC: A61K039/02 ,  C12N009/00 ,  C07K016/12

CPC classification number: C07K14/212 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/1203 ,  C07K16/1214 ,  C07K16/1217 ,  C07K2317/73 ,  C07K2317/734 ,  Y02A50/396

Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to M. catarrhalis and M. catarrhalis OMP106 polypeptides and OMP106-derived polypeptides in animals.

Abstract translation: 本发明公开了卡他莫拉菌外膜蛋白-106（OMP106）多肽，由其衍生的多肽（OMP106衍生多肽），编码所述多肽的核苷酸序列，以及特异性结合OMP106多肽和/或OMP106衍生多肽的抗体。 还公开了免疫原性，预防性或治疗性组合物，包括疫苗，其包含OMP106多肽和/或OMP106衍生的多肽。 本发明另外公开了在动物体内诱导针对卡他莫拉菌和卡他莫拉菌OMP106多肽和OMP106衍生多肽的免疫应答的方法。

公开(公告)号：US5759813A

公开(公告)日：1998-06-02

申请号：US193150

申请日：1994-09-19

Applicant: Eric J. Hansen ,  Isobel Maciver ,  Merja Helminen

Inventor： Eric J. Hansen ,  Isobel Maciver ,  Merja Helminen

IPC: A61K39/095 ,  A61K38/00 ,  A61K39/00 ,  A61K39/02 ,  A61K39/395 ,  A61P31/04 ,  C07K14/195 ,  C07K14/21 ,  C07K16/00 ,  C07K16/12 ,  C12N1/21 ,  C12N15/00 ,  C12N15/02 ,  C12N15/09 ,  C12N15/31 ,  C12P21/00 ,  C12P21/08 ,  C12R1/01 ,  C12R1/19 ,  C12R1/91 ,  G01N33/53 ,  G01N33/569 ,  G01N33/577 ,  C12P21/06 ,  C07H21/02 ,  C07H21/04

CPC classification number: C07K16/1203 ,  C07K14/212 ,  C07K16/1217 ,  A61K38/00 ,  A61K39/00

Abstract: The present disclosure relates to selected antigenic proteins obtained from the outer membranes of Moraxella catarrhalis, that are found to have a variety of useful properties. These proteins, termed OMPs ("Outer Membrane Proteins"), are characterized as having molecular weights of about 30 kD, 80 kD and between about 200 and 700 kD, respectively. Studies set forth herein demonstrated that monoclonal antibodies directed against these proteins confer a protective effect against infection by Moraxella catarrhalis organisms in animal models, demonstrating the potential usefulness of such antibodies in conferring passive immunity as well as the potential usefulness of these OMPs, or variants thereof, in the preparation of vaccines. Also disclosed are DNA segments encoding these OMPs, methods for preparing the antigens or variants, through the application of recombinant DNA techniques, as well as diagnostic methods and embodiments.

Abstract translation: 本公开涉及从被认为具有多种有用特性的莫拉氏卡他莫拉菌的外膜获得的所选抗原蛋白质。 称为OMP（“外膜蛋白”）的这些蛋白质的特征在于分子量分别为约30kD，80kD和约200和700kD之间。 本文所述的研究证明，针对这些蛋白质的单克隆抗体在动物模型中赋予针对卡他莫拉菌生物体的感染的保护作用，表明这些抗体在赋予被动免疫力方面的潜在用途以及这些OMP或其变体的潜在有用性 ，在疫苗的制备中。 还公开了编码这些OMP的DNA区段，通过应用重组DNA技术制备抗原或变体的方法，以及诊断方法和实施方案。

公开(公告)号：US5057598A

公开(公告)日：1991-10-15

申请号：US304884

申请日：1989-02-01

Applicant: Matthew Pollack ,  Kenneth W. Hunter

Inventor： Matthew Pollack ,  Kenneth W. Hunter

IPC: A61K38/00 ,  C07K16/12 ,  G01N33/569

CPC classification number: C07K16/1203 ,  G01N33/56911 ,  A61K38/00 ,  G01N2400/50 ,  Y10S424/803 ,  Y10S530/806 ,  Y10S530/808 ,  Y10S530/825

Abstract: Novel monoclonal antibodies are disclosed, the production of which is specified by particular genes contained, conveniently, in biologically pure cultures of self-reproducing carrier cells, such as, but not limited to, ATCC HB 8297 and ATCC HB 8298, such antibodies being reactive with at least part of endotoxin core of Gram-negative bacteria. Processes of prepaU.S. GOVERNMENT RIGHTSThe invention described herein may be manufactured, used and licensed by or for the U.S. Government for governmental purposes only without the payment to the inventors of any royalties thereon.

Abstract translation: 公开了新的单克隆抗体，其生产由特定的基因所指定，方便地在自我繁殖载体细胞的生物纯纯培养物中包括但不限于ATCC HB 8297和ATCC HB 8298，所述抗体是反应性的 至少部分革兰氏阴性细菌的内毒素核心。 公开了制备自体繁殖载体细胞的方法，例如ATCC HB 8297和ATCC HB 8298。 还公开了从载体细胞制备抗体的方法，其方便地是细胞系如杂交瘤。 进一步公开的是使用这种抗体的免疫诊断和免疫检测组合物和方法。 还进一步公开了使用抗体的免疫预防和免疫治疗组合物和方法。 还公开了使用抗体的研究组合物和方法。 并且甚至进一步公开了利用该抗体的组合物和方法，其可用于从含有它的溶液或混合物中纯化或除去内毒素。